This web only provides the extract of this article. If you want to read the figures and tables, please reference the PDF full text on Blackwell Synergy. Thank you.
- Original Article -
Prostate cancer antigen-1 as a potential novel marker for
prostate cancer
Bing-Qian Liu1, Yu-Dong
Wu1, Pei-Huan Li2, Jin-Xing
Wei1, Tong Zhang3, Ran-Lu
Liu4
1Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
2Department of Pathology, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical
College, Tianjin 300020, China
3Department of Urology, Shandong Provincial Hospital, Jinan 250021, China
4Tianjin Institute of Urology, Second hospital of Tianjin Medical University, Tianjin 300211, China
Abstract
Aim: To examine the expression of prostate cancer antigen-1 (PCA-1) in prostate cancer (PCa) and to validate it as
a potential marker for diagnosis of PCa. Methods:
In situ hybridization analysis of PCA-1 mRNA expression was
performed on 40 benign prostate hyperplasia (BPH), 16 high-grade prostatic intraepithelial neoplasm (HG-PIN), 74
PCa and 34 other malignant carcinoma specimens. The level of PCA-1 expression was semiquantitatively scored by
assessing both the percentage and intensity of PCA-1 positive staining cells in the specimens. We then compared the
PCA-1 expression between BPH, HG-PIN and PCa and evaluated the correlation of PCA-1 expression level with
clinical parameters of PCa. Results: PCA-1 mRNA was expressed in the majority of both PCa and HG-PIN
specimens but not in BPH and other malignant carcinoma. The expression level of PCA-1 increased along with a high
Gleason score (P < 0.05), and was unrelated to other clinical parameters of PCa (all
P > 0.05). Conclusion:
The data suggest that PCA-1 might be a novel diagnostic marker for PCa, and that increased PCA-1 expression might
denote more aggressive variants of PCa. (Asian J Androl 2007 Nov; 9: 821_826)
Keywords: marker; prostate cancer; prostate cancer antigen-1
Correspondence to: Dr Bing-Qian Liu, Department of Urology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,
China.
Tel: +86-371-6691-3287 Fax:
+86-371-6778-3222
E-mail: liubq76@yahoo.com.cn
Received: 2006-08-11 Accepted 2007-01-22
DOI: 10.1111/j.1745-7262.2007.00279.x
1 Introduction
Prostate cancer (PCa) is the most common malignancy in men in the United States and is becoming an
increasingly common cancer in China. PCa carcinogenesis is related to several genetic changes. Previous studies have
identified several genes that are overexpressed or underexpressed in PCa, but few specific molecular markers for PCa
have been found [1, 2]. Prostate specific antigen (PSA) has been widely used as a diagnostic marker for PCa.
However, elevated levels of PSA can also be found in benign prostate hyperplasia (BPH) and prostatitis [3, 4].
Therefore, there is an urgent need for one or more sensitive and specific markers that can detect PCa in its early
stages.
Konishi et al. [5] reported that prostate cancer
antigen-1 (PCA-1) is predominantly prostate specific, and
found that PCA-1 is overexpressed in PCa [5]. We
further investigated the status of PCA-1 mRNA expression
in different prostate samples and identify it as a potential
diagnostic marker for PCa by using in situ hybridization
(ISH). Moreover, we evaluated the possible correlation
of PCA-1 expression level with clinical parameters of
PCa.
2 Materials and methods
2.1 Tissue samples
In the present study, all the prostate tissue
specimens were obtained from 130 patients of 55_78 years
old at the department of Urology of the First Affiliated
Hospital of Zhengzhou University (Zhengzhou, China).
They were undergoing biopsies, transuretheral resections
of the prostate or open prostatectomy. None of the
patients had received preoperative hormonal therapy,
chemotherapy and actinotherapy. The patients were
classified into 40 cases of BPH, 16 cases of high-grade
prostatic intraepithelial neoplasm (HG-PIN) and 74 cases of
primary PCa. In addition, there were other malignant
carcinomas, including 5 cases of thyroid cancer, 9 cases
of bladder cancer, 4 cases of kidney cancer, 6 cases of
colon cancer, 5 cases of liver cancer and 5 cases of breast
cancer. Each tissue sample was treated with 4%
paraformaldehyde/0.1 mol/L phosphate-buffered saline
(PBS) pH 7.4 in 0.1% DEPC for 1 h for ISH analysis. All
the used samples were analyzed by two experienced
urological pathologists to ensure that the samples contained
predominantly epithelial cells (in BPH samples) or
carcinoma cells (in PCa samples). This project was approved
by the Research Ethics Committee of Zhengzhou University.
2.2 Preparation of cRNA probes
Total RNA of PCa tissue was isolated by using a total
RNA isolation kit (Promega, Madison, USA). A sample
of 2 µg total RNA was used in a reverse transcription
reaction. Primers set for PCA-1 were: sense,
5'-GGA TCC TTT ATC GCA ATG AGA AGG-3' (BamHI site
underlined); antisense, 5'-AAG CTT TGT CCG AAA GGT
CAG GTT-3' (HindIII site underlined). Polymerase chain
reaction (PCR) protocol (94ºC 30 s, 50ºC 20 s, 72ºC 30 s)
was run for 30 cycles and PCR product was approximately 104 bp. PCR product was separated by
electrophoresis, recovered with a gel extraction kit
(Omega, Doraville, USA) and ligated with pGEM-T vector. The ligate was transformed into competent
Escherichia coli JM 109 cells. The correct transformant
was identified by restriction enzyme analysis. Large
quantities of plasmid were then harvested with a Plasmid
Extraction Kit (Promega, Madison, USA). After
linearization by NcoI restriction enzyme, SP6 promoter was used
to drive the transcription of PCA-1-cRNA probes
in vitro, and in this system Biotin labeled rUTP was introduced
into PCA-1-cRNA probes. In the same way, after
linearization by NotI restriction enzyme, T7 promoter was
used to drive the transcription of sense PCA-1-cRNA
probes in vitro, which acted as the negative control.
2.3 In situ hybridization
Five μm sections were deparaffinized in xylene (7.5 min, twice) and dehydrated in graded thanol, then
digested in pepsin solution (4 mg/mL in 3% citric acid)
for 20 min at 37ºC, followed by rinsing in PBS at room
temperature, and processing for ISH.
Digoxigenin-labeled human PCA-1 RNA probes were hybridized to the
sections at 48ºC overnight, under glass coverslips
specific for ISH. The highest stringent post-hybridization
washes were 37ºC in 2 × standard saline citrate (SSC)
for 10 min, 0.5 × SSC for 15 min and 0.2 × SSC for
30 min. Subsequently, the slides were incubated with
biotinylated mouse anti-digoxigenin antibody at 37.5ºC
for 1 h followed by washing in 1× PBS for 20 min at
room temperature, and then with strepavidin-peroxidase
at 37.5ºC for 20 min followed by washing in 1 × PBS for
20 min at room temperature. Subsequently, a drop of
3,3'-diaminobenzedine was added and color was developed. Counterstaining was performed using
hematoxylin to localize the hybridization signals. All slides
were hybridized with PBS or the sense probe to
substitute for the antisense probe as a negative control.
2.4 Scoring methods
The intensity of PCA-1 expression was graded on a
scale of 0_3, with 3 being the highest expression
observed (0, no staining; 1, mildly intense; 2, moderately
intense; 3, severely intense). The staining density was
quantified as the percentage of cells staining positive for
PCA-1, as follows: 0, no staining; 1, < 20% of tumor
cells were positive; 2, > 20% but < 50% of tumor cells
were positive; 3, > 50% of tumor cells were positive.
Intensity score was multiplied by the density score to
give an overall score of 0_9 [6]. The overall score for
each specimen was then categorially assigned to one of
the following groups: 0_1 scores, negative expression
(_); 2_3 scores, weak expression (+); 4_9 scores, strong
expression (++).
2.5 Statistical analysis
PCA-1 mRNA expression in HG-PIN and PCa tissues
were compared by using the χ2-test.
The correlation between PCA-1 expression and clinical parameters of PCa
were also calculated by using the
χ2-test. For all analyses,
P < 0.05 was considered statistically significant.
3 Results
3.1 Gain of PCA-1 cDNA fragment
We successfully cloned a 104-bp fragment by reverse transcription-PCR, then the fragment was ligated
with pGEM-T vector and the recombinant vector was named pGEM-T-PCA. pGEM-T-PCA and was digested
by BamH I and HindIII enzymes, yielding a 3.0-kb
fragment of vector and a 104-bp fragment of PCA-1
cDNA(Figure 1). We confirmed PCA-1 cDNA by sequencing,
which was completely identical to the sequence in Genbank. Sequencing revealed that no base mutation
occurred in the sequence of our cloned PCA-1-cDNA fragment.
3.2 PCA-1 expression in different specimens
We found that PCA-1 expression was positive in
82.4% (61 of 74) of PCa samples. Positive staining was
confined to cancerous cells in PCa and was not seen either
in adjacent normal cells or in BPH. Interestingly, of the
16 HG-PIN found in this series of prostate specimens,
62.5% (10 of 16) of the HG-PIN samples were found to
be positive for PCA-1 staining (Table 1). PCA-1
staining was most often exhibited by atypical epithelia in
HG-PIN (Figure 2). Little or no PCA-1 protein expression
was observed in samples of thyroid cancer, bladder
cancer, kidney cancer, colon cancer, liver cancer and
breast cancer, suggesting that expression of PCA-1 is
specific to PCa.
3.3 Correlation of PCA-1 expression with clinical
parameters of PCa
The relationship between PCA-1 staining and clinical
parameters of PCa is summarized in Table 2. Of Gleason
scores of 8_10, seventy-two percent had very strong
staining of PCA-1 compared with 39% of Gleason scores
of 5_7 and 23% of Gleason scores of 2_4,
demonstrating that poorly differentiated PCa had significantly stronger
expression of PCA-1 than moderately and
well-differentiated PCa (P < 0.05). No statistically significant
difference was found between the PCA-1 expression and age,
serum PSA level, prostate volume, osseous metastasis
or clinical stage (all P > 0.05).
4 Discussion
Alkylation is one of the mechanisms by which nucleic
acids can be altered. Alkylating agents are ubiquitous in
our environment and are endogenously produced during
cellular metabolism. DNA alkylation can induce mutation,
inhibit replication, and is implicated in carcinogenesis [7].
This harmful modification is repaired by demethylation.
DNA alkylation damage repair mechanisms are best
studied in E. coli and be controlled by six genes [8]. The
AlkB gene of these genes can be induced upon exposure to a
sublethal dose of alkylating agents, called the adaptive
response. The AlkB protein can evidently repair both ssDNA
and RNA modifications generated by SN2 methylating
reagents [9, 10]. Damaged repair mechanisms would lead
to carcinogenesis. Konishi N et al. [5] identify a new gene,
PCA-1, which has high homology to E. coli
alkB. PCA-1 cDNA transfection partially reversed the cell death of
COS-7 cells exposed to an SN2 alkylation agent,
methylmethane sulfonate. Therefore, we hypothesize that
PCA-1 might play a role in PCa tumorigenesis, and might
serve as a marker for PCa diagnosis.
We successfully cloned a 104-bp fragment of
PCA-1. The full length of PCA-1-cDNA was 1 520 bp and the
cloned fragment was located in the 5'-terminal of the full
length. The fragment had high specificity and nonhomology with other genes by BLAST analysis, so it
was equal to probes in the screening of gene expression.
To further evaluate the finding that PCA-1 was overexpressed in PCa samples, we performed ISH
analysis. The studies revealed that the positive
expression rate of PCA-1 is 82.4% in PCa samples, but that
there is no expression in BPH and other carcinoma tissues,
suggesting that expression of PCA-1 is specific to PCa.
It is well known that HG-PIN is generally accepted to be
a premalignant lesion [11]. Characterization of
precursor lesions is very important both for clinical diagnosis
and management of PCa. Therefore, the identification
of a new marker to detect the premalignant lesion is
invaluable. Interestingly, the positive expression rate of
PCA-1 is 62.5% in HG-PIN, and only expressed in
atypical cells. These findings suggest that PCA-1 expression
might be related to neoplastic transformation in the
prostate. We found no significant correlation between
PCA-1 expression and age, tumor volume, PSA, osseous
metastasis or tumor stage. Therefore, we suggested that
PCA-1 is as a sensitive and specific marker for detecting
and monitoring prostate neoplasias.
We found significant correlation between PCA-1
expression and Gleason scores, and determined that an
elevated level of PCA-1 expression correlates with high
grade. It is suggested that PCA-1 overexpression might
be an adverse predictor for clinical progression of PCa.
It is well known that the biological behavior of PCa
varies widely. The clinical discrepancy might be a
consequence of heterogeneity of gene expression [12, 13]. The
different levels of PCA-1 expression might reflect this
characteristic heterogeneity in PCa. From our results, it
is suggested that PCA-1 as a new marker might have a
number of potential uses in the progression and
prognosis of human PCa.
The cause of PCA-1 overexpression in PCa is not
known. However, as a DNA repair enzyme, variant
levels of PCA-1 expression among different prostate
tissues might be related to various types and degrees of
carcinogen exposure.
In summary, we have shown in this study that
PCA-1 is overexpressed in a majority of PCa as well as
HG-PIN, which correlates positively with tumor grade.
Although more studies are needed to determine the role of
PCA-1 in human cells and the relationship between
prostate carcinogenesis and overexpression, the present
results suggest that PCA-1 might be a promising
molecular marker for the clinical prognosis of human PCa and a
specific target for diagnosis of human PCa.
References
1 Kumar-Sinha C, Chinnaiyan AM. Molecular markers to
identify patients at risk for recurrence after primary treatment for
prostate cancer. J Urol 2003; 62: 19_35.
2 Gray JM. Population screening and patient testing using PSA.
BJU Int 2005; 95: 3.
3 Hara N, Kitamura Y, Saito T, Komatsubara S. Total and free
prostate-specific antigen indexes in prostate cancer screening:
value and limitation for Japanese populations. Asian J Androl
2006; 8: 429_34.
4 Li XM, Zhang L, Li J, Li Y, Wang HL, Ji GY,
et al. Measurement of serum zinc improves prostate cancer detection
efficiency in patients with PSA levels between 4 ng/mL and 10
ng/mL. Asian J Androl 2005; 7: 323_8.
5 Konishi N, Nakamura M, Ishida E, Shimada K, Mitsui E,
Yoshikawa R, et al. High expression of a new marker PCA-1
in human prostate carcinoma. Clin Cancer Res 2005; 11: 5090_7.
6 Zhao ZG, Shen WL. Prostate stem cell antigen (PSCA)
expression in human prostate cancer tissues and its potential
role in prostate carcinogenesis and progression of prostate
cancer. World J Surg Oncol 2004; 2: 13_20.
7 Mishina Y, Duguid EM, He C. Direct reversal of DNA
alkylation damage. Chem Rev 2006; 106: 215_32.
8 Sedgwick B, Lindahl T. Recent progress on the Ada response
for inducible repair of DNA alkylation damage. Oncogene 2002;
21: 8886_94.
9 Dinglay S, Trewick SC, Lindahl T, Sedgwick B. Defective
processing of methylated single-stranded DNA by
E. coli AlkB mutants. Genes Dev 2000; 14: 2097_105.
10 Aas PA, Otterlei M, Falnes PO, Vagbo GB, Skorpen F, Akbari
M, et al. Human and bacterial oxidative demethylases repair
alkylation damage in both RNA and DNA. Nature 2003; 421:
859_63.
11 Sofikerim M, Tatlisen A, Karacagil M. Do all patients with
high-grade prostatic intraepithelial neoplasia on initial
prostatic biopsy eventually progress to clinical prostate cancer?
BJU Int 2006: 97: 869_70.
12 Dakubo GD, Parr RL, Costello LC, Franklin RB, Thayer RE.
Altered metabolism and mitochondrial genome in prostate
cancer. J Clin Pathol 2006; 59: 10_6.
13 Konishi N, Nakamura M, Kishi M, Nishimine M, Ishida E,
Shimada K. Heterogeneous methylation and deletion patterns
of the INK4a/ARF locus within prostate carcinomas. Am J
Pathol 2002; 160:1207_14.
|